Envestnet Asset Management Inc. Has $7.38 Million Position in Fresenius Medical Care AG & Co. KGaA $FMS

Envestnet Asset Management Inc. lowered its holdings in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 25.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 280,178 shares of the company’s stock after selling 93,783 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $7,377,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. TD Waterhouse Canada Inc. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter valued at $36,000. Atlantic Union Bankshares Corp bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter worth about $43,000. Hantz Financial Services Inc. raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 568.5% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock worth $59,000 after acquiring an additional 1,768 shares during the last quarter. Huntington National Bank lifted its position in Fresenius Medical Care AG & Co. KGaA by 219.5% in the 2nd quarter. Huntington National Bank now owns 2,355 shares of the company’s stock valued at $67,000 after acquiring an additional 1,618 shares in the last quarter. Finally, AlphaCore Capital LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 2nd quarter valued at about $73,000. Institutional investors own 8.37% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on FMS shares. Weiss Ratings downgraded Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 5th. Truist Financial set a $28.00 price target on Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Erste Group Bank cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Finally, The Goldman Sachs Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Five analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Stock Up 1.2%

FMS stock opened at $24.40 on Friday. The stock has a market cap of $14.15 billion, a P/E ratio of 17.81, a P/E/G ratio of 0.76 and a beta of 0.90. The company has a current ratio of 1.36, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45. The stock’s fifty day simple moving average is $23.32 and its two-hundred day simple moving average is $24.47. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $20.94 and a 1-year high of $30.46.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.